stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Current ratio
Erasca, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 8.3×, down 1.7× from fiscal 2025 (10.0×). Over the past ten years it has ranged from 8.8× (fiscal 2020) to 18.6× (fiscal 2019); the current reading is higher than 57% of that period. That is above the Biotechnology industry median of 5.0× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 10.0× | 2.07% |
| FY2024 | 9.8× | (19.77%) |
| FY2023 | 12.3× | 34.30% |
| FY2022 | 9.1× | (43.00%) |
| FY2021 | 16.0× | 82.61% |
| FY2020 | 8.8× | (52.82%) |
| FY2019 | 18.6× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 8.3× | (12.86%) |
| Mar 2026 | 9.5× | (5.20%) |
| Dec 2025 | 10.0× | (3.89%) |
| Sep 2025 | 10.4× | (5.34%) |
| 19 more quarters | Free account |
Against its own ten years
Low 8.8×
High 18.6×
Ten-year median
10.0×
Current reading's percentile
57
Current ratio against peers
| Company | Current ratio |
|---|---|
| MANE Veradermics Incorporated compare | 70.5× |
| DNTH Dianthus Therapeutics, Inc. compare | 30.0× |
| CRSP CRISPR Therapeutics AG compare | 16.2× |
| COGT Cogent Biosciences, Inc. compare | 13.6× |
| EWTX Edgewise Therapeutics, Inc. compare | 12.3× |
| ERAS Erasca, Inc. | 8.3× |
| DFTX Definium Therapeutics, Inc. compare | 6.9× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 3.0× |
| TVTX Travere Therapeutics, Inc. compare | 3.0× |
| Biotechnology industry median | 5.0× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)